Impact of austerity on European pharmaceutical policy and pricing
Staying competitive in a challenging environment
Deloitte UK Centre for Health Solutions report addresses current challenges faced by the pharmaceutical industry due to on-going austerity in Europe
The current financial climate has placed significant pressure on public spending and while the majority of governments’ acknowledge healthcare provision to be strategically important, their willingness and ability to pay is subject to increasing pressures.
As a high percentage of healthcare costs are fixed and difficult to tackle in the short term, governments are adopting a number of aggressive pricing strategies to exert downward pressure on consumables, including drugs.